

1 **Sestrins induce natural killer function in senescent-like CD8<sup>+</sup> T cells**

2 Branca I. Pereira<sup>1†</sup>, Roel P. H. De Maeyer<sup>1†</sup>, Luciana P. Covre<sup>1,2†</sup>, Djamel Nehar-Belaid<sup>3†</sup>,  
3 Alessio Lanna<sup>1,4</sup>, Sophie Ward<sup>5</sup>, Radu Marches<sup>3</sup>, Emma S. Chambers<sup>1</sup>, Daniel C. O. Gomes<sup>2</sup>,  
4 Natalie E. Riddell<sup>1,6</sup>, Mala K. Maini<sup>1</sup>, Vitor H. Teixeira<sup>7</sup>, Samuel M. Janes<sup>7</sup>, Derek W. Gilroy<sup>8</sup>,  
5 Anis Larbi<sup>9</sup>, Neil A. Mabbott<sup>10</sup>, Duygu Ucar<sup>3</sup>, George A. Kuchel<sup>11</sup>, Sian M. Henson<sup>12</sup>, Jessica  
6 Strid<sup>5</sup>, Jun H. Lee<sup>13</sup>, Jacques Banchereau<sup>3</sup>, Arne N. Akbar<sup>1\*</sup>

7

8 **Affiliation:**

9 <sup>1</sup> Division of Infection and Immunity, University College London, London, UK.

10 <sup>2</sup> Núcleo de Doenças Infecciosas, Universidade Federal do Espírito Santo, Vitória, Brazil.

11 <sup>3</sup> The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA.

12 <sup>4</sup> Nuffield Department of Medicine, University of Oxford, Oxford, UK.

13 <sup>5</sup> Department of Medicine, Imperial College London, London, UK.

14 <sup>6</sup> Faculty of Health & Medical Sciences, University of Surrey, Guildford, UK.

15 <sup>7</sup> Lungs for Living Research Centre, UCL Respiratory, University College London, London UK.

16 <sup>8</sup> Division of Medicine, University College London, London, UK.

17 <sup>9</sup> Singapore Immunology Network (SIgN), Agency for Science, Technology and Research  
18 (A\*STAR), Immunos Building, Biopolis, Singapore, Singapore.

19 <sup>10</sup> Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh,  
20 Edinburgh, UK.

21 <sup>11</sup> University of Connecticut Center on Aging, University of Connecticut, Farmington,  
22 Connecticut, USA.

23 <sup>12</sup> William Harvey Research Institute, Barts and The London School of Medicine and Dentistry,  
24 Queen Mary University of London, London, UK.

25 <sup>13</sup> Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor,  
26 Michigan, USA.

27

28 † These authors contributed equally.

29

30 **\*Corresponding author:**

31 **Professor Arne N Akbar**

32 Division of Infection and Immunity, University College London,

33 Rayne Institute, 5 University Street, London, WC1E 6JF

34 Email: a.akbar@ucl.ac.uk

35 **Abstract**

36 Ageing is associated with re-modelling of the immune system to enable the maintenance of  
37 life-long immunity. In the CD8<sup>+</sup> T cell compartment, ageing results in the expansion of highly-  
38 differentiated cells that exhibit characteristics of cellular senescence. Here we found that  
39 CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T lost the signalling activity of the T cell antigen receptor (TCR) and  
40 expressed a protein complex containing the agonistic NK receptor NKG2D and the NK adaptor  
41 molecule DAP12, which promoted cytotoxicity against cells that expressed NKG2D ligands.  
42 Immunoprecipitation and imaging cytometry indicated that the NKG2D-DAP12 complex was  
43 associated with sestrin 2. The genetic inhibition of sestrin 2 resulted in decreased expression  
44 of NKG2D and DAP12 and restored TCR signaling in senescent-like CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells.  
45 Therefore, during ageing, sestrins induces the reprogramming of non-proliferative senescent-  
46 like CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells to acquire a broad-spectrum, innate-like killing activity.

47

48 Immunity declines during ageing and this is associated with an increased incidence of  
49 infections and malignancy<sup>1</sup>. It is therefore essential to understand mechanisms that contribute  
50 to altered immunity in older individuals in order to identify possible therapeutic targets.  
51 Because the thymus involutes from puberty onwards, its contribution to the maintenance of  
52 the T cell pool decreases considerably during ageing. Instead, antigen specific T cells are  
53 maintained in older individuals by repeated episodes of activation and proliferation triggered  
54 by specific or cross-reactive antigenic challenge or by homeostatic cytokines<sup>2</sup>. This extensive  
55 proliferative activity leads ultimately to extreme functional differentiation and the development  
56 of T cell senescence associated with telomere erosion, decreased signalling through the T cell  
57 antigen receptor (TCR), activation of the telomere-extending enzyme telomerase and growth  
58 arrest<sup>3-5</sup>. Because the replicative activity of T cells is impaired as senescence develops,  
59 mechanisms other than T cell proliferation may be required to maintain optimal immune  
60 protection during ageing.

61 Highly-differentiated CD8<sup>+</sup> T cells that lose expression of the surface receptors CD28 and  
62 CD27 (CD27<sup>-</sup>CD28<sup>-</sup>) exhibit senescent-like characteristics that include low proliferative  
63 activity, short telomeres, low telomerase activity and expression of senescence-associated  
64 cell surface (CD57 and KLRG1) and intracellular (the MAP kinase p38,  $\gamma$ H2AX) molecules<sup>4</sup>.  
65 CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells also upregulate receptors associated with natural killer (NK) cells,  
66 such as inhibitory (KLRG1, NKG2A) and activatory proteins (NKG2C and NKG2D)<sup>6</sup>. Whether  
67 the acquisition of the senescence-like characteristics and the expression of NK receptors  
68 (NKR) are linked or are controlled independently remains unclear.

69 Sestrins are stress-sensing proteins, induced by conditions of low glucose or oxidative stress  
70 or cellular senescence, that inhibit TCR activation and CD4<sup>+</sup> T cell proliferation in both mice  
71 and humans<sup>7</sup>. Here we showed that sestrins inhibited the expression of the TCR signaling  
72 molecules LAT, ZAP70 and LCK in mouse and human CD8<sup>+</sup> T cells, and concomitantly  
73 induced the expression of both inhibitory and activatory NKRs. Furthermore, sestrins  
74 regulated the association of NKG2D with the scaffold protein DAP12, which converts it into an

75 activating receptor that can trigger the secretion of cytokines and cytotoxicity towards target  
76 cells bearing NKG2D ligands, independently of the TCR. Collectively, these data indicated  
77 that senescent-like CD8<sup>+</sup> T cells were not a defective end-stage population. Instead these  
78 cells, while non-proliferative, were instead re-programmed during differentiation to recognize  
79 and kill through both TCR<sup>8</sup> as well as NKR recognition mechanisms, a process regulated by  
80 the sestrins. The repurposing of senescent-like CD8<sup>+</sup> T cells to mediate innate-like functional  
81 activity may be crucial to mitigate against the increased burden of tumours and stromal  
82 senescent cells that accumulate in tissues during ageing<sup>9,10</sup>.

83

## 84 **Results**

### 85 **Human CD8<sup>+</sup> T<sub>EMRA</sub> cells upregulate NKRs but decrease TCR components**

86 First, we isolated peripheral blood CD8<sup>+</sup> T cell subsets from six healthy donors and compared  
87 the transcriptomes of CD27<sup>+</sup>CD45RA<sup>-</sup>CD8<sup>+</sup> central memory T cells (T<sub>CM</sub> cells), CD27<sup>-</sup>  
88 CD45RA<sup>-</sup> CD8<sup>+</sup> effector memory T cells (T<sub>EM</sub> cells) and CD27<sup>-</sup>CD45RA<sup>+</sup>CD8<sup>+</sup> terminal effector  
89 memory T cells (T<sub>EMRA</sub> cells) relative to the CD27<sup>+</sup>CD45RA<sup>+</sup>CD8<sup>+</sup> naïve T cells (T<sub>N</sub> cells) using  
90 Affymetrix U133 plus 2 microarrays (**Fig. 1a** and **Extended Data Fig. 1a**). Differentially  
91 expressed genes in these CD8<sup>+</sup> T cell subsets were identified based on a minimum of a 2-fold  
92 change ( $p < 0.05$ , false-discovery rate (FDR) for multiple comparisons  $< 0.05\%$  (Supplementary  
93 table 1). Hierarchical clustering of genes associated with effector cell function indicated a  
94 transcriptional signature that distinguished T<sub>EMRA</sub> cells from T<sub>N</sub> cells (**Fig. 1b,c**). Genes  
95 involved in co-stimulation (*Cd28*, *Cd27*), TCR signaling (*Trac*, *Cd3e*, *Cd3g*, *Lck*, *Lat*, *Plcg1*)  
96 and proliferation and cell cycle control (*Ccne1*, *Ccnd3*) were downregulated in T<sub>EMRA</sub> cells  
97 compared to T<sub>N</sub> cells (**Fig. 1b,c**). Compared to CD8<sup>+</sup> T<sub>N</sub> cells, CD8<sup>+</sup> T<sub>EMRA</sub> cells upregulated  
98 genes encoding the transcription factors *Zeb2* (fold change: 10.75,  $p < 0.0001$ ) and *Zbtb16*  
99 (encoding PLZF, fold change: 6.48,  $p < 0.0001$ , **Fig. 1b**, Supplementary Table 2) which are  
100 known to regulate terminal differentiation of memory T cells<sup>11</sup> and the development of innate-

101 like features in T cells in mice<sup>12,13</sup>. *Zbtb16* was also increased in T<sub>CM</sub> cells and T<sub>EM</sub> cells  
102 compared to T<sub>N</sub> cells (7.7- and 4.8-fold respectively; Supplementary table 2). T<sub>EMRA</sub> cells  
103 upregulated genes encoding NKRs (including *Kir* family members, *Nkg2a/c* and *Klrg1*), innate  
104 signalling adaptors (*Tyrobp*, encoding DAP12) and molecules involved in cytotoxicity  
105 (*Gzma/b*, *Prf*, *Fasl*, *Itgav* and *Itgb1*)<sup>14</sup>. T<sub>EMRA</sub> cells also upregulated chemokine receptors  
106 associated with the migration of NK cells into tissues (*Cx3cr1*, *S1pr5*, and *Cmklr1*)<sup>15</sup>, indicating  
107 that the differentiation of CD8<sup>+</sup> T cells from T<sub>N</sub> cells into T<sub>EMRA</sub> cells was associated with a  
108 transcriptional program that promoted cytotoxic effector functions at the expense of  
109 proliferative potential and suggested that highly-differentiated CD8<sup>+</sup> T cells may express  
110 effector functions independent of the TCR.

111 Flow cytometric analysis indicated that the expression of NKRs on non-NK cells was elevated  
112 on CD3<sup>+</sup>CD27<sup>-</sup>CD45RA<sup>+</sup>CD8<sup>+</sup> T<sub>EMRA</sub> cells (**Fig. 1d, Extended Data 1a**) in PBMCs isolated  
113 from a separate cohort of healthy donors (n = 22; median age = 52; range = 25-83). The  
114 repertoire of NKRs expressed on CD8<sup>+</sup> T<sub>EMRA</sub> cells was diverse and included both activating  
115 (NKG2D, NKG2C and KIR2DS) and inhibitory (NKG2A, KIR2DL/KIR3DL and CD244)  
116 receptors, as well as the maturation markers KLRG1 and CD57 (**Fig. 1d, Extended Data 1b**).  
117 Expression of CD28 and CD27 is sequentially lost on CD8<sup>+</sup> T cells as they transition from  
118 CD27<sup>+</sup>CD28<sup>+</sup> CD8<sup>+</sup> T<sub>N</sub> cells to CD27<sup>+</sup>CD28<sup>-</sup> intermediate CD8<sup>+</sup> T cells and to terminal, or  
119 senescent-like, CD27<sup>-</sup>CD28<sup>-</sup> CD8<sup>+</sup> T cells<sup>16,17</sup>. To analyse the expression of the TCR signalling  
120 machinery in CD8<sup>+</sup> T<sub>EMRA</sub> cells, we isolated CD8<sup>+</sup> T cell subsets by their relative expression of  
121 CD27 and CD28, as the use of CD27 and CD28 as markers enabled the isolation of more  
122 cells for functional analyses. The CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cell subset contained the T<sub>EMRA</sub> subset  
123 and T<sub>EM</sub> subset (**Extended Data 1c**) and had increased expression of NKRs compared to  
124 CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup> T<sub>N</sub> cells (**Extended Data 2a**). Senescent-like CD8<sup>+</sup> T cells, either identified  
125 as CD27<sup>-</sup>CD28<sup>-</sup><sup>18,19</sup> or as CD27<sup>-</sup>CD45RA<sup>+20</sup> increase in both number and proportion during  
126 ageing and exhibit markers of senescence<sup>4,5,7,20</sup>. Immunoblots showed a significant  
127 downregulation of LCK, LAT and PLC-γ1, but upregulation of ZAP70 in CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T

128 cells compared to CD8<sup>+</sup> T<sub>N</sub> cells (**Fig. 1e**). CD27<sup>-</sup>CD28<sup>-</sup>CD4<sup>+</sup> T cells also acquired cell-surface  
129 expression of NKR (including KLRG1, NKG2C and NKG2D), but to a lower degree than  
130 CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells (**Extended Data 2b**). Together, these findings indicated the  
131 increased expression of NKR on CD8<sup>+</sup> T cells with characteristics of terminal differentiation  
132 and senescence.

### 133 **Individual T<sub>EMRA</sub> CD8<sup>+</sup> T cells are senescent and express NKR and cytotoxic molecules**

134 To investigate whether NKR, cytotoxicity-related molecules and senescence markers were  
135 expressed on individual CD8<sup>+</sup> T<sub>EMRA</sub> cells, we used single cell RNA-sequencing (scRNA-seq)  
136 to investigate the transcriptomes of ~62,000 CD8<sup>+</sup> T cells isolated from six healthy old donors  
137 (72-88 yrs). CD8<sup>+</sup>IL-7R<sup>+</sup> and CD8<sup>+</sup>IL-7R<sup>-</sup> T cells were sorted from each donor resulting in 12  
138 samples (**Extended Data 3a**). Sorts yielded an average of 6199 CD8<sup>+</sup>IL-7R<sup>+</sup> cells (SD 1582)  
139 and 4192 CD8<sup>+</sup>IL-7R<sup>-</sup> cells (SD 1269) per donor, with an average of 1043 and 1011 genes per  
140 cell, respectively (**Extended Data 3b,c**). After discarding hybrid transcriptomes (multiplets)  
141 using Scrublet (Methods), raw data from the 12 samples (six CD8<sup>+</sup>IL-7R<sup>+</sup> and six CD8<sup>+</sup>IL-7R<sup>-</sup>  
142 T cells) were combined. scRNA-seq profiles that passed the quality control (**Extended Data**  
143 **3d**) were then corrected for technical batch effects (e.g. 10x run) using BBKNN. Unbiased  
144 clustering followed by a two-dimensional uniform manifold approximation and projection  
145 (UMAP) on the corrected data identified 13 distinct clusters (**Fig. 2a**). Cluster assignments  
146 were independent of batch (**Extended Data 3e**) and donor (**Extended Data 3f**) effects. The  
147 CD8<sup>+</sup>IL-7R<sup>+</sup> and CD8<sup>+</sup>IL-7R<sup>-</sup> groups associated with distinct sets of clusters (**Fig. 2b**). The  
148 number of cells within each cluster varied from 9,263 to 915 (**Extended Data 3g**) and their  
149 expression of *Il7r* mRNA was confirmed (**Extended Data 4a**). We assigned clusters to cell  
150 types based on differential analysis comparing expression values among cells from a given  
151 cluster to all other cells (Supplementary Table 3). All clusters expressed transcripts for *Cd3e*  
152 and *Cd8*, but not *Cd4* (**Fig. 2c**). We could identify clusters of T<sub>N</sub> cells (expressing *Cd27*, *Ccr7*,  
153 *Sell* or *Cd28*) and effector T cells (expressing *Klrg1*, *Prf1* or *Gzmb*) (**Fig. 2c**). Based on this  
154 expression profile, clusters C0, C4 and C8 were defined as CD8<sup>+</sup> T<sub>N</sub> cells, and C1, C2 and C6

155 as CD8<sup>+</sup> T<sub>EMRA</sub> cells (**Fig. 3a**). A second round of clustering performed on these six clusters  
156 confirmed the distinct transcriptomic profiles of the CD8<sup>+</sup> T<sub>N</sub> and CD8<sup>+</sup> T<sub>EMRA</sub> compartments  
157 (**Fig. 3b, Extended Data 4b**) and confirmed the enrichment of the CD8<sup>+</sup>T<sub>EMRA</sub> compartment  
158 within the CD8<sup>+</sup>IL-7R<sup>-</sup> cells (**Extended Data 4c**). CD8<sup>+</sup> T<sub>N</sub> cells were characterized by the  
159 expression of *Cd27*, *Cd28*, *Ccr7* and *Sell*, while CD8<sup>+</sup> T<sub>EMRA</sub> cells showed an upregulation of  
160 *Klrg1*, *Prf1* or *Gzmb* relative to the clusters of CD8<sup>+</sup> T<sub>N</sub> cells (**Extended Data 4d**).

161 The expression of 15 NK-associated genes, including *Fcgr3a* (encoding the Fcγ receptor  
162 CD16), the NK-related receptors *Fcrl6*, *Klrc1* and *-2*, *Klrg1* and *Tyrobp* (**Fig. 3c**) was used to  
163 define an “NK score”. This confirmed that CD8<sup>+</sup> T<sub>EMRA</sub> cells become NK-like compared to CD8<sup>+</sup>  
164 T<sub>N</sub> cells (**Fig. 3d**; Supplementary Table 4). Similarly, we used expression of senescence-  
165 related genes, such as *B3gat1* (encoding the enzyme that creates the CD57 epitope), the cell  
166 cycle regulators *Cdkn1a* and *Cdkn2a*, and sMAC components such as *Sesn2* and *Mapk1* to  
167 create a “senescence score” to determine whether CD8<sup>+</sup> T<sub>EMRA</sub> cell were senescent compared  
168 to CD8<sup>+</sup> T<sub>N</sub> cells (**Fig. 3e,f**, Supplementary Table 4). Although expression of LCK, PLC-γ1 and  
169 LAT proteins was decreased in CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells compared to T<sub>N</sub> CD8<sup>+</sup> cells (**Fig. 1e**),  
170 the mRNA for these TCR signalling components was similar in CD8<sup>+</sup> T<sub>EMRA</sub> and CD8<sup>+</sup> T<sub>N</sub> cells  
171 analysed by scRNA-seq (not shown), suggesting their expression might be regulated by post-  
172 translational modification in CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells. These observations suggested that  
173 CD8<sup>+</sup> T<sub>EMRA</sub> cells had characteristics of cellular senescence and expressed a range of NKRs,  
174 NK adaptors and cytotoxic mediators.

### 175 **NKG2D and DAP12 induce cytotoxicity in senescent CD8<sup>+</sup> T cells**

176 We next investigated whether CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells had NK cell-like functions  
177 independently of TCR-MHC interactions. Based on the expression of the degranulation marker  
178 CD107a<sup>21</sup>, CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells killed K562 cells, an MHC class I-deficient tumour cell  
179 line, with the same efficiency as NK cells (**Fig. 4a**). These data were confirmed using a calcein-  
180 release assay (**Extended Data 5a,b**). To address whether NKG2D mediated the cytotoxic



181 activity of CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells, we knocked down NKG2D in CD28<sup>-</sup>CD8<sup>+</sup> T cells with a  
182 small interfering RNA (siRNA) specific for NKG2D (siNKG2D CD8<sup>+</sup>T cells) and assessed their  
183 ability to kill MHC class I-deficient C1R cells transfected with the NKG2D ligand MICA\*008  
184 (C1R-MICA cells) when co-cultured for 6 hours (**Extended Data 5c,d**). CD28<sup>-</sup>CD8<sup>+</sup>T cells  
185 transfected with scrambled siRNA (siCtrl) showed increased degranulation, measured by  
186 CD107a exposure, towards C1R-MICA compared to C1R cells, while the cytotoxicity of  
187 siNKG2D CD8<sup>+</sup> T cells towards the C1R-MICA cells was inhibited compared to siCtrl (**Fig. 4b**),  
188 indicating that CD28<sup>-</sup>CD8<sup>+</sup> T cells could kill target cells in a manner dependent on NKG2D.

189 Expression of NKG2D on the cell surface requires its association with adaptor proteins that  
190 stabilise the immunoreceptor complex and provide it with signalling activity<sup>22</sup>. NKG2D  
191 associates with the adaptor molecules DAP10 and DAP12. DAP10 contains an YxxM-motif  
192 that activates PI3K<sup>23,24</sup>, while DAP12 has an ITAM-motif that can recruit and activate ZAP70-  
193 Syk triggering cytokine release and cytotoxicity<sup>25-27</sup>. In human CD8<sup>+</sup> T cells, NKG2D is  
194 predominantly associated with DAP10<sup>23,27</sup> (**Extended Data 5e**), which allows it to act as a co-  
195 stimulatory signal for the TCR. Immunoblot analysis (**Fig. 4c**) and intracellular flow cytometry  
196 (**Fig. 4d**) indicated increased expression of DAP12 in CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells compared to  
197 CD8<sup>+</sup> T<sub>N</sub> cells, corresponding to the transcriptomic data indicating that *Tyrobp* (which encodes  
198 DAP12) was strongly induced in CD8<sup>+</sup> T<sub>EMRA</sub> cells compared to CD8<sup>+</sup> T<sub>N</sub> cells. To investigate  
199 whether the killing activity of CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells was mediated by DAP12 association  
200 with NKG2D, we immunoprecipitated NKG2D from CD28<sup>+</sup>CD8<sup>+</sup> or CD28<sup>-</sup>CD8<sup>+</sup> T cells isolated  
201 from peripheral blood of healthy donors. DAP12 associated with NKG2D only in the CD28<sup>-</sup>  
202 CD8<sup>+</sup> T cells (**Fig. 4e**).

203 We next investigated whether ligation of NKG2D induced the phosphorylation of ZAP70-Syk  
204 in CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells. CD3 ligation with a monoclonal antibody (mAb) against CD3  
205 induced the phosphorylation of ZAP70-Syk, as expected, while using an NKG2D mAb alone  
206 induced more p-ZAP70 and p-Syk compared to a CD3 mAb alone (**Fig. 4f**), indicating that  
207 CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells can be activated by both the TCR and NKG2D, but show an

208 increased propensity to respond to the latter. NKG2D stimulation alone was sufficient to induce  
209 expression of granzyme B and secretion of the cytokine IFN- $\gamma$  in CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells  
210 (**Fig. 4g**). siRNA-mediated silencing of DAP12 in CD28<sup>-</sup>CD8<sup>+</sup> T cells impaired the cytolytic  
211 degranulation of CD28<sup>-</sup>CD8<sup>+</sup> T cells towards C1R-MICA cells compared to scrambled siRNA  
212 control-transfected CD28<sup>-</sup>CD8<sup>+</sup> T cells (**Fig. 4h**). Thus, DAP12 expression was upregulated in  
213 CD28<sup>-</sup>CD8<sup>+</sup> T cells and was necessary and sufficient to mediate NKG2D-dependent  
214 cytotoxicity.

### 215 **Sestrins block TCR signalling but increase NKR in CD8<sup>+</sup> T cells**

216 CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells have reduced proliferative activity after TCR stimulation<sup>4,5,7</sup>. We  
217 investigated whether reduced expression of the components of the CD3-TCR complex  
218 compromised the efficiency of proximal TCR signaling. Phospho-flow cytometry indicated  
219 impaired phosphorylation of CD3 $\zeta$  after stimulation with CD3 antibodies in CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup>  
220 compared to CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup> T cells (**Fig. 5a**). Although the expression of total ZAP70 was  
221 increased in CD28<sup>-</sup>CD27<sup>-</sup>CD8<sup>+</sup> T cells (**Fig. 1e**), its phosphorylation was impaired in these  
222 cells compared to CD28<sup>+</sup>CD27<sup>+</sup>CD8<sup>+</sup> T cells following CD3 activation (**Fig. 5b**).

223 The stress-sensing proteins sestrins induce characteristics of senescence in CD4<sup>+</sup> T cell by  
224 forming a complex with the kinase AMPK and the MAP kinases that is inhibitory for signalling  
225 through the TCR<sup>7</sup>. Flow cytometry (**Fig. 5c,d**) and immunoblotting (**Fig. 5e**) indicated that  
226 human peripheral blood CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells from young subjects (<40 yrs) exhibited  
227 increased expression of sestrin 1 and sestrin 2 compared to CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup> T cells. Sestrin  
228 2 was upregulated in total CD8<sup>+</sup> T cells from donors older than 65 years compared to those  
229 between 18-35 years (**Extended Data 5f**). In addition, CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells had increased  
230 amounts of activated Jnk MAP kinase (p-Jnk) compared to CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup> T cells (**Fig.**  
231 **5e**). Immunoprecipitation experiments indicated that DAP12, sestrin 2 and Jnk were  
232 associated with NKG2D in CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells (**Fig. 6a**), while imaging cytometry  
233 indicated that sestrin 2, DAP12 and p-Jnk co-localised in CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells, but not in

234 CD8<sup>+</sup> T<sub>N</sub> cells (**Fig. 6b,c**). These observations suggested that sestrin 2 associated with  
235 NKG2D-DAP12-Jnk in CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> cells.

236 Next, we tested whether sestrins regulated the expression of NKG2D in human CD28<sup>-</sup>CD8<sup>+</sup> T  
237 cells. Peripheral blood CD28<sup>-</sup>CD8<sup>+</sup> T cells isolated from healthy donors (median age = 39;  
238 range = 25-70) were lentivirally transduced with shRNA against sestrin 1, 2 and 3 (shSesn)  
239 had significantly reduced expression of DAP12 (**Fig. 6d**) and NKG2D compared to CD28<sup>-</sup>CD8<sup>+</sup>  
240 T cells transduced with control vectors (**Fig. 6e**), indicating sestrins modulated the expression  
241 of NKG2D in these cells. siRNA-mediated depletion of Jnk (**Fig. 6f**) or its inhibition with the  
242 small molecule inhibitor SP-600125 in CD28<sup>-</sup>CD8<sup>+</sup> T cells (**Fig. 6g**) reduced the expression of  
243 NKG2D, increased the frequency of CD28<sup>+</sup> cells and restored proximal TCR signalling  
244 following CD3 ligation compared to untreated CD28<sup>-</sup>CD8<sup>+</sup> T cells (**Fig. 6f,g**). This indicated a  
245 reconstitution of T cell-related functions, implying sestrins may act through Jnk to induce  
246 expression of NKG2D expression in CD28<sup>-</sup>CD8<sup>+</sup> T cells.

247

#### 248 **YFV induces the upregulation of NKR on CD8<sup>+</sup> T cells**

249 Next we tested if the upregulation of NKRs by CD8<sup>+</sup> T cells occurred exclusively as a result of  
250 cellular senescence or if NKRs were expressed on less-differentiated subsets of CD8<sup>+</sup> T cells  
251 in response to antigenic stimulation, and the expression was maintained as cells differentiated  
252 towards senescence. Using publicly available RNA-seq gene expression data generated in a  
253 cohort of 12 individuals vaccinated against yellow fever<sup>28</sup>, we compared CD8<sup>+</sup> T effector (T<sub>E</sub>  
254 cells), defined as CD8<sup>+</sup> YFV-tet<sup>+</sup> cells that were present at day 14 post-vaccine, and CD8<sup>+</sup> T  
255 memory (T<sub>M</sub> cells) defined as CD8<sup>+</sup> YFV-tet<sup>+</sup> cells that were present 4-13 years post-vaccine,  
256 to YFV-tet<sup>-</sup> CD8<sup>+</sup> T<sub>N</sub> cells. Cytotoxic mediators such as *Fasl*, *Prf1*, *Gzma* and *Gzmb* were highly  
257 expressed in CD8<sup>+</sup> T<sub>E</sub> cells and CD8<sup>+</sup> T<sub>M</sub> cells compared to CD8<sup>+</sup> T<sub>N</sub> T cells (**Extended Data**  
258 **6**). Additionally, there was a significant upregulation of multiple NKRs, including many of the  
259 *Kir*, *Fcgr3a*, *Cd57* and *Klrc1* on CD8<sup>+</sup> T<sub>E</sub> cells and CD8<sup>+</sup> T<sub>M</sub> cells compared to CD8<sup>+</sup> T<sub>N</sub> cells, as

260 well as chemokine receptors (*S1pr5*, *Cmklr1* and *Cx3cr1*) and NK adaptor proteins such as  
261 *Tyrobp* (**Extended Data 6**). The upregulation of these molecules occurred on YFV-tet<sup>+</sup>CD8<sup>+</sup>  
262 T<sub>E</sub> cells during the effector phase of the response and was maintained in long-lived YFV-tet<sup>+</sup>  
263 T<sub>M</sub> cells (**Extended data 6**). Based on published data, YFV-tet<sup>+</sup> T<sub>M</sub> cells lack markers of  
264 senescence like CD57, are CD27<sup>+</sup>CD28<sup>+</sup> and are polyfunctional with regard to cytokine  
265 secretion<sup>29</sup>. Unlike the CD8<sup>+</sup> T<sub>EMRA</sub> cells, YFV-tet<sup>+</sup>CD8<sup>+</sup> T<sub>M</sub> cells exhibit proliferative potential  
266 *in vitro*, suggesting that they are not terminally differentiated<sup>29</sup>. YFV-tet<sup>+</sup>CD8<sup>+</sup> T<sub>E</sub> and T<sub>M</sub> cells  
267 showed slight downregulation of the TCR signalosome (*Lat*, *Plcg1*, *Zap70*) compared to CD8<sup>+</sup>  
268 T<sub>N</sub> cells (**Extended Data 6**). Of note, sestrin 2 was upregulated in the YFV-tet<sup>+</sup>CD8<sup>+</sup> T<sub>E</sub> and  
269 T<sub>M</sub> cells compared to CD8<sup>+</sup> T<sub>N</sub> cells (**Extended data 6**). This analysis indicated that the  
270 expression of NKR on CD8<sup>+</sup> T cells was not limited to senescent CD27<sup>-</sup>CD28<sup>-</sup>CD8 T cells but  
271 was also a feature of YFV-tet<sup>+</sup>CD8<sup>+</sup> T<sub>E</sub> and T<sub>M</sub> cells after activation *in vivo*.

272

### 273 **Sestrins regulate the function of CD8<sup>+</sup> T cells *in vivo***

274 Sestrins regulate the decreased function of CD4<sup>+</sup> T cells in aged mice and humans<sup>7</sup>. We next  
275 investigated if sestrins directly regulated the expression of NKRs in CD8<sup>+</sup> T cells in young (~6  
276 weeks) and old (~18 months) wild-type mice and old (~18 months) *Sesn1*<sup>-/-</sup> and *Sesn2*<sup>-/-</sup> mice.  
277 Mice were vaccinated subcutaneously against methylated BSA (mBSA) and re-challenged  
278 with mBSA in the footpad two weeks later to induce a delayed-type hypersensitivity (DTH)  
279 response as an index of successful immune induction. All mice mounted a DTH response to  
280 the re-challenge, but the DTH response in old wild-type, *Sesn1*<sup>-/-</sup> and *Sesn2*<sup>-/-</sup> mice resulted in  
281 increased footpad swelling compared to young wild-type mice (**Fig. 7a**). The response  
282 resolved more slowly in old wild-type compared to young wild-type mice, while old *Sesn1*<sup>-/-</sup>  
283 and *Sesn2*<sup>-/-</sup> mice resolved faster than old wild-type mice (**Fig. 7a,b**). Spleen weights were  
284 equivalent in all groups post-mBSA challenge (**Extended Data 7a**). There were no changes  
285 in the proportions of splenic NK cells, iNKT cells, CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells in all old and

286 young mice following the DTH response (**Extended Data 7b,c**). However, CD44<sup>+</sup>CD62L<sup>-</sup>CD8<sup>+</sup>  
287 T effector cells (T<sub>EFF</sub> cells) expanded, while CD44<sup>-</sup>CD62L<sup>+</sup>CD8<sup>+</sup> T<sub>N</sub> cells decreased in old wild-  
288 type mice, but not in old *Sesn1*<sup>-/-</sup> and *Sesn2*<sup>-/-</sup> mice, compared to young wild-type mice  
289 (**Extended Data 7d,e**).

290 Expression of NKG2D and DAP12, as well as NKG2A, NKG2C, NKG2E and Ly49 was higher  
291 on the CD8<sup>+</sup> T cells from the old wild-type mice compared to young wild-type mice, whereas  
292 their expression was lower in old *Sesn1*<sup>-/-</sup> and *Sesn2*<sup>-/-</sup> mice compared to old wild-type mice  
293 (**Fig. 7c-e and Extended Data Fig. 7f**), suggesting the expression of these receptors was  
294 modulated by sestrins. Importantly, the expression of NKG2D, as well as NKG2A, NKG2C,  
295 NKG2E on CD3<sup>+</sup>TCRβ<sup>+</sup>NK1.1<sup>+</sup> NK cells or TCRβ<sup>+</sup>CD1d-tet<sup>+</sup> iNKT cells was similar in young  
296 wild-type, old wild-type and old *Sesn1*<sup>-/-</sup> and *Sesn2*<sup>-/-</sup> mice (**Fig. 7f**), indicating that sestrins  
297 uniquely regulated the expression of NKR in CD8<sup>+</sup> T cells. To examine the effect of sestrin  
298 deficiency on the cytotoxic function of CD8<sup>+</sup> T cells *in vivo*, 24-month old wild-type mice and  
299 24-month old *Sesn1*<sup>-/-</sup>*Sesn2*<sup>-/-</sup>*Sesn3*<sup>+/-</sup> mice were depleted of NK cells by intra-peritoneal  
300 treatment with an NK1.1 Ab prior to intra-venous injection of equal numbers of 5tgm1 myeloma  
301 cells expressing Rae-1, the mouse equivalent of MICA/B, and Rae-1<sup>-</sup> splenocytes. Six hours  
302 post-transfer of target cells, more Rae-1<sup>+</sup> 5TGM1 cells were detected in the spleens of *Sesn1*<sup>-/-</sup>  
303 *Sesn2*<sup>-/-</sup>*Sesn3*<sup>+/-</sup> mice compared to wild-type mice (**Fig. 7h**). This resulted from decreased  
304 specific lysis of Rae-1<sup>+</sup> 5TGM1 target cells in *Sesn1*<sup>-/-</sup>*Sesn2*<sup>-/-</sup>*Sesn3*<sup>+/-</sup> mice compared to wild-  
305 type mice (**Fig. 7h**). These observations indicated that the sestrins regulated the expression  
306 of NKG2D and DAP12 and conferred NK cell-like cytotoxic activity to CD8<sup>+</sup> T cells of old mice  
307 *in vivo*.

308

## 309 **Discussion**

310 Here we provide phenotypic, functional and mechanistic data to indicate that as CD8<sup>+</sup> T cells  
311 differentiated towards senescence they lost the expression of co-stimulatory molecules such  
312 as CD28 and CD27 and downregulated TCR signalling molecules such as Lck and LAT, while

313 upregulating the expression of NKRs such as NKG2D, NKG2A and CD16. Compared to  
314 CD28<sup>+</sup>CD27<sup>+</sup>CD8<sup>+</sup> T cells, CD28<sup>-</sup>CD27<sup>-</sup>CD8<sup>+</sup> T cells acquired a senescent phenotype.  
315 Expression of NKRs was associated with acquisition of the ability to kill tumour cells in vitro  
316 and in vivo through an NKR-dependent process. The downregulation of TCR-related signalling  
317 molecules concomitantly with the acquisition of NKR-related molecules was regulated by  
318 sestrins.

319

320 Altered TCR signalling pathways in iNKT and antigen-specific CD8<sup>+</sup> T cells result in the  
321 development of unconventional functions that are not restricted to TCR-MHC interactions<sup>30,31</sup>.  
322 The suppression of TCR signalling, along with an acquired responsiveness to innate stimuli  
323 was proposed to be a characteristic that defines innate-like T cells<sup>32</sup>. Here, we found that the  
324 TCR to NKR functional switch in CD8<sup>+</sup> T cells was dependent on the kinase Jnk, similar to  
325 previous findings in CD4<sup>+</sup> T cells<sup>7</sup>. The mechanism by which sestrins modulate this transition  
326 remains unclear. Experiments in sestrin-deficient mice indicated that sestrins did not regulate  
327 the expression of NKRs in NK cells or iNKT cells, and it remains unclear if sestrins may  
328 regulate the function of other types of innate-like T cells e.g.  $\gamma\delta$  T cells.

329

330 The reprogramming of CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells from TCR to NKR functional activity could be  
331 particularly relevant for CD8<sup>+</sup> T cells specific for persistent pathogens, such as  
332 cytomegalovirus (CMV) and Epstein-Barr virus (EBV), which accumulate during ageing<sup>33-35</sup>.  
333 Our data suggest that in addition to their role in maintaining long-term specific immunity  
334 against these viruses, these cells may also recognize virus-infected cells or tumour cells  
335 through an NK cell-like, antigen-independent manner, thus enabling them to exhibit broad  
336 protective functions.

337

338 Our observations raise questions about the biological significance of such changes and the  
339 possible advantage of generating T cells with NK cell-like characteristics. The accumulation  
340 of CD8<sup>+</sup> T<sub>EMRA</sub> cells was reported to be a predictor of successful ageing<sup>8</sup>. One reason for this  
341 may be that acquisition of NKRs by CD8<sup>+</sup> T<sub>EMRA</sub> cells might allow them to broaden their  
342 capacity for immune surveillance by utilising different recognition systems, thereby partly  
343 compensating for decreased output of T<sub>N</sub> cells in older subjects and reduced TCR-mediated  
344 classical T cell function<sup>36</sup>. Given the increased burden of tumours and infections with age, the  
345 expansion of NK cell-like functions in CD8<sup>+</sup> T cells could be an advantageous adaptation that  
346 would enable the recognition of transformed cells.

347

348 Senescent cells are pro-inflammatory and increase in number in many tissues during  
349 ageing<sup>37,38</sup>. The removal of these senescent tissue cells enhances organ function and retards  
350 age-related functional decline<sup>39,40</sup>. Because NK cells and CD8<sup>+</sup> T cells can recognize and kill  
351 senescent cells via NKG2D mediated mechanisms<sup>9,10,41</sup>, NKR-expressing CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup>  
352 T cells may participate in the surveillance and elimination of senescent tissue cells. Based on  
353 the observations here that sestrins regulate functional fate decisions in T cells, it will be  
354 important to identify if these molecules also have similar roles in other cell types.

355

356 It is important to know when the expression of sestrins and NKRs are induced on T cells after  
357 vaccination. Gene expression studies in YFV-specific CD8<sup>+</sup> T cells from previously non-  
358 immunized young individuals (<40 years) vaccinated with the yellow fever virus vaccine  
359 showed that expression of NKRs and sestrins was upregulated in the effector phase of the  
360 response (2 weeks post-vaccination) and maintained in the CD8<sup>+</sup> T<sub>M</sub> cells for years  
361 afterwards<sup>28,29</sup>. This indicates that sestrins are not only induced when CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T  
362 cells become senescent. Naïve CD27<sup>+</sup>CD28<sup>+</sup> T cells within the CD4 compartment of old  
363 individuals (>65 yrs) have been shown to express a significantly higher level of sestrins than

364 naïve CD27<sup>+</sup>CD28<sup>+</sup>CD4<sup>+</sup> T cells from young individuals<sup>7</sup> suggesting that this molecule will  
365 have an impact on vaccine responses, that induce the expansion of naïve T cell precursors,  
366 during ageing. It is not clear if naïve YFV-specific CD8<sup>+</sup> T cell precursors in old humans  
367 express higher levels of sestrins and if these cells can be activated optimally after vaccination.  
368 Nevertheless, it has been shown that in old mice, sestrin inhibition can enhance the number  
369 of influenza-specific CD4<sup>+</sup> T cells after influenza vaccination *in vivo*<sup>7</sup>. This may be a strategy  
370 to also enhance the response to other vaccines during ageing. A caveat is that the long-term  
371 blockade of sestrins with either specific inhibitors or by transfection with inhibitory shRNA may  
372 be dangerous, as it could enhance the proliferation of senescent-like T cells that harbour DNA  
373 damage. However, the temporary blockade of sestrins may be a safe strategy to increase the  
374 number of antigen-specific T cells after vaccination to enhance immunity during ageing<sup>7</sup>.

375

### 376 **Acknowledgements**

377 We thank A. Toubert from INSERM U.1160 and laboratoire d'Immunologie et  
378 d'Histocompatibilité, Hôpital Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité for the  
379 kind gift of the C1R-MICA cell line. B.I.P. was supported by the Portuguese Foundation for  
380 Science and Technology and Gulbenkian Institute for Science sponsoring the Advanced  
381 Medical Program for Physicians (PFMA). This work was supported by the Medical Research  
382 Council (grant MR/P00184X/1 to A.N.A), the Ministry of Education of Brazil (Grant  
383 BEX9414/14-2 to L.P.C.), the Wellcome Trust (Grant AZR00630 to A.Lanna), UCL Business  
384 to S.M.H and A.N.A (for the microarray work), the National Institutes of Health (R01DK102850  
385 and R01DK111465 to J.H.L.), the NIH/NIAID (R01 AG052608 and R01 AI142086) to JB and  
386 the Biotechnology and Biological Science Research Council (Grant BB/L005336/1 to N.E.R.).  
387 R.P.H.D was supported, in part, by the NIHR UCLH Biomedical Research Centre, S.M.H. is  
388 funded by the Springboard award from the Academy of Medical Science and the Wellcome  
389 Trust. A.L. is a Sir Henry Wellcome Trust Fellow sponsored by Prof. Michael L. Dustin  
390 (University of Oxford). S.M.J. is a Wellcome Trust Senior Fellow in Clinical Science and is  
391 supported by the Rosetrees Trust, the Welton Trust, the Garfield Weston Trust and UCLH



392 Charitable Foundation. S.M.J. and V.H.T. have been funded by the Roy Castle Lung Cancer  
393 Foundation. DU is supported by National Institute of General Medical Sciences (NIGMS) under  
394 award number GM124922. GAK is supported by the Travelers Chair in Geriatrics and  
395 Gerontology, as well as National Institute on Aging (AG061456; AG048023; AG063528;  
396 AG060746; AG021600; AG052608; AG051647).

397

398 **Author contributions:** B.I.P., L.P.C and R.P.H.D. designed and performed the experiments,  
399 analysed the data and wrote the manuscript. DNB designed and analysed the single cell RNA-  
400 seq data under the supervision of JB and DU. RM performed all the experiments with the  
401 healthy older adult subjects. GAK recruited all the healthy older adult donors subjects in  
402 Farmington. CT. A. Lanna, E.S.C. and N.E.R. designed and performed experiments. S.W. and  
403 J.S. designed and performed *in vivo* cytotoxicity studies. S.M.H. and A.N.A. designed and  
404 performed the microarray studies. A. Larbi provided support for studies of NKR on T cells.  
405 N.A.M., V.H.T. and S.M.J. analysed the microarray and RNA-seq data. D.C.O.G., D.W.G.,  
406 J.H.L. and M.K.M. facilitated mouse experiments. D.E. designed and provided the lentiviral  
407 vectors. A.N.A. designed the experiments and reviewed and edited the manuscript and  
408 organized the collaborative infrastructure.

409

410 **Competing interests:** The authors have declared that no conflict of interest exists.

411

## 412 **Materials and Methods**

### 413 ***Study design***

414 The study protocol was approved by the Ethical Committee of the Royal Free and University  
415 College London Medical School (Research Ethics number: 11/0473). Written informed  
416 consent was obtained from all study participants. Donors did not have any co-morbidity, were  
417 not on any immunosuppressive drugs, and retained physical mobility and lifestyle

418 independence. For analyses involving the CD8<sup>+</sup> T cell, IL-7R<sup>+</sup>/IL-7R<sup>-</sup> single cell dataset studies  
419 were conducted following approval by the Institutional Review Board (IRB) of the University of  
420 Connecticut Health Center (IRB 14-194J-3). After receiving informed consent, blood samples  
421 were obtained from 6 healthy old (>65 year old) research volunteers residing in the Greater  
422 Hartford, CT, region using services of the University of Connecticut Center on Aging  
423 Recruitment and Community Outreach Research Core and following previously published  
424 screening criteria (PMID:28904110).

425

### 426 ***Cell isolation and transfection***

427 Peripheral blood mononuclear cells (PBMC) were isolated by density gradient (Ficoll–  
428 Hypaque, Amersham Biosciences, UK) from heparinized blood of healthy donors (n = 22, 26–  
429 83 years). Untouched NK and CD8<sup>+</sup> T cells were freshly isolated by magnetic activated cell  
430 sorting (MACS, Miltenyi Biotec, UK) using a negative selection procedure. For microarray  
431 analysis, high-purity CD8<sup>+</sup> T cell subsets were sorted on the basis of CD27 and CD45RA  
432 expression<sup>42</sup>, using a FACS Aria (BD Biosciences, UK) flow cytometer. For functional assays,  
433 CD8<sup>+</sup> T cell subsets were freshly isolated according to CD27/CD28 expression by magnetic  
434 activated cell sorting (MACS, Miltenyi Biotec, UK), which identified analogous subsets but  
435 provided higher yields of viable cells (> 95% purity) as previously described<sup>5,7</sup>. Double  
436 negative cells were obtained by complete negative isolation. We found that <1% of cells within  
437 these isolated populations expressed iNKT markers. Mucosal associated invariant T cells  
438 (MAIT) cells express TCR Vα7.2 and these cells constitute ~5% of the peripheral CD8<sup>+</sup> T cells  
439 pool in humans<sup>43</sup>. We found 4% (range 1-7.5%) of these cells in isolated CD28<sup>+</sup> CD27<sup>+</sup>, 3%  
440 (range 1-6.4) in the isolated CD28<sup>-</sup>CD28<sup>+</sup> and 2.9% (range 1-4.9%) in the isolated CD28<sup>-</sup>CD27<sup>-</sup>  
441 CD8<sup>+</sup> T cells populations. The results obtained are therefore unlikely to be due to  
442 contaminating iNKT or MAIT cells in our CD8<sup>+</sup> T cells populations.

443 Where indicated, freshly purified human CD8<sup>+</sup> T cells were transfected with small interfering  
444 RNA (siRNA) for NKG2D (Santa Cruz Biotechnology, sc-42948) or DAP12 (sc-35172) by  
445 electroporation using the Amaxa Human NK Cell Nucleofector Kit and Nucleofector  
446 technology (Lonza), according to the manufacturer's instructions. A scrambled control siRNA  
447 (sc-37007; Santa Cruz) was used throughout. Efficiency of siRNA transfection was confirmed  
448 by measuring the expression of the protein of interest using flow cytometry, 36-48 hours after  
449 transfection.

#### 450 ***Microarray data acquisition***

451 Cells purified by FACS were stimulated for 2 hours with 0.5 µg/ml plate-coated anti-CD3  
452 (OKT3) and 5 ng/ml rhIL-2 before RNA isolation using the ARCTURUS PicoPure Isolation Kit  
453 (ThermoFisher). The concentration of small quantities of RNA was determined using  
454 Nanodrop. Linear amplification of 10 ng of total RNA was performed using the Ovation Biotin  
455 RNA amplification and labelling system (NuGEN). Fragmented, labelled cDNA was hybridized  
456 to Affymetrix U133 plus 2 arrays.

#### 457 ***Single cell RNA sequencing***

458 **Sample processing:** all samples were processed within one hour from venipuncture.

459 **Cell Sorting:** PBMCs were isolated from fresh whole blood using Ficoll-Paque Plus (GE)  
460 density gradient centrifugation. For cell sorting, we used fluorochrome-labeled antibodies  
461 specific for CD3 (UCHT1), CD27 (M-T271) (Biolegend), CD4 (RPA-T4), CD19 (HIB19), IgD  
462 (IA6-2), CD127 (HIL-7R-M21) (BD Biosciences), and CD8 (SCF121Thy2D3) (Beckman-  
463 Coulter). CD8<sup>+</sup>IL7R<sup>+</sup> (CD8<sup>+</sup>CD127<sup>+</sup>) and CD8<sup>+</sup>IL7R<sup>-</sup> (CD8<sup>+</sup>CD127<sup>-</sup>) T cells were sorted from  
464 the CD19<sup>-</sup>CD3<sup>+</sup>CD4<sup>-</sup> fraction. Cell sorting was performed using FACS Aria Fusion (BD).

465 **Blood preparation for single cell RNA sequencing (scRNA-seq):** PBMCs were thawed  
466 quickly at 37°C and transferred to DMEM supplemented with 10% FBS. Cells were spun down  
467 at 400 g, for 10 min. Cells were washed once with 1 x PBS supplemented with 0.04% BSA  
468 and finally re-suspended in 1 x PBS with 0.04% BSA. Viability was determined using trypan

469 blue staining and measured on a Countess FLII and samples with <80% viability were  
470 discarded. 12,000 cells were loaded for capture onto the Chromium System using the v2 single  
471 cell reagent kit (10X Genomics). Following capture and lysis, cDNA was synthesized and  
472 amplified (12 cycles) as per manufacturer's protocol (10X Genomics). The amplified cDNA  
473 was used to construct an Illumina sequencing library and sequenced on a single lane of a  
474 HiSeq 4000.

475 **Single cell Raw data processing and data combination:** Illumina basecall files (\*.bcl) were  
476 converted to fastqs using cellranger v2.1.0, which uses bcl2fastq v2.17.1.14. FASTQ files  
477 were then aligned to hg19 genome and transcriptome using the cellranger v2.1.0 pipeline,  
478 which generates a gene - cell expression matrix. The samples were merged together using  
479 cellranger aggr from cellranger, which aggregates outputs from multiple runs, normalizing  
480 them to the same sequencing depth (normalize=mapped) and then re-computing the gene-  
481 barcode matrices and analysis on the combined data (See scripts here:  
482 <https://github.com/dnehar/Temra-IL7R-Senescence>).

483 **Scrublet for multiplet prediction and removal:** Generally, we expected about 2 to 8% of  
484 the cells to be hybrid transcriptomes or multiplets, occurring when two or more cells are  
485 captured within the same microfluidic droplet and are tagged with the same barcode. Such  
486 artifactual multiplets can confound downstream analyses. We applied Scrublet<sup>44</sup> python  
487 package to remove the putative multiplets. Scrublet assigns each measured transcriptome a  
488 'multiplet score', which indicates the probability of being a hybrid transcriptome. Multiplet  
489 scores were determined for each individual (using the raw data), and 0.7% - 10.7% highest  
490 scoring cells were tagged as multiplets after visual inspection of doublet score distributions  
491 and excluded from the further analysis.

492 **Single cell processing, clustering and cell type classification:** The aggregated matrices  
493 were fed into the Python-based ScanPy<sup>45</sup> workflow (<https://scanpy.readthedocs.io/en/stable/>),  
494 which includes preprocessing, visualization, clustering and differential expression testing. The  
495 pipeline we used was inspired by The Seurat<sup>46</sup> R package workflow.

496 **Quality control and cell-filtering:** We applied the following filtering parameters: (i) all genes  
497 that were not detected in  $\geq 3$  cells were discarded, (ii) cells with less than 400 total unique  
498 transcripts were removed prior to downstream analysis, (iii) cells in which  $> 20\%$  of the  
499 transcripts mapped to the mitochondrial genes were filtered out, as this can be a marker of  
500 poor-quality cells and (iv) cells displaying a unique gene counts  $> 2,500$  genes were  
501 considered outliers and discarded.

502 **Data normalization:** After discarding unwanted cells from the dataset, we normalized the  
503 data. Library-size normalization was performed based on gene expression for each barcode  
504 by scaling the total number of transcripts per cell to 10,000. We log-transformed the data and  
505 then regressed out using the total number of genes and the fraction of mitochondrial transcript  
506 content per cell. 1202 highly variable genes (HVG) were identified using  
507 `filter_genes_dispersion` scanpy function and used to perform the principal component analysis  
508 (PCA).

509 **Linear dimensional reduction using PCA and graph-based clustering:** Dimensionality  
510 reduction was carried out in SCANPY via principal component analysis followed by Louvain  
511 clustering UMAP visualization using the top 40 significant components (PCs)<sup>47</sup>.

512 **Finding marker genes/evaluation of cluster identity:** To annotate the cell type of each  
513 single cell transcriptome, we used both differential expression analysis between clusters and  
514 classification based on putative marker gene expression. We applied the  
515 '`tl.rank_genes_groups`' scanpy function to perform differential analyses, comparing each  
516 cluster to the rest of the cell using Wilcoxon test (Supplementary Table 3). We only considerate  
517 clusters that showed a distinct transcriptomic programs.

518 **Batch effect correction:** We performed a batch (10X genomics batch) correction using  
519 BBKNN (<https://github.com/Teichlab/bbknn>)<sup>48</sup>. More details about the parameters used can  
520 be found as a Jupyter notebook here: <https://github.com/dnehar/Temra-IL7R-Senescence>.

521 **NK and Senescence scores:**

522 Gene lists (Table S3) were used to score NK or senescence expression in naïve and Temras  
523 CD8 T cells. To do so, we calculated the mean expression for each cell, within each cluster  
524 using the h5ad object (adata), as follow:

```
525 adata.obs['NK_score'] = adata.X[:,NK_markers].mean(1).
```

526 The scores were then plotted, as shown in Fig .3D.

### 527 ***Lentiviral transduction***

528 Sestrin knockdown in human CD8<sup>+</sup> T cells was achieved using a lentiviral transduction system  
529 as described previously<sup>9</sup>.

530 The pHIV1-SIREN-GFP system used for knockdown of gene expression possesses a U6-  
531 shRNA cassette to drive shRNA expression and a GFP reporter gene that is controlled by a  
532 PGK promoter<sup>5</sup>. The following siRNA sequences were used for gene knockdowns:  
533 CCTAAGGTTAAGTCGCCCTCG (shCTRL), CCAGGACCAATGGTAGACAAA (shSesn1),  
534 CCGAAGAATGTACAACCTCTT (shSesn2) and CAGTTCTCTAGTGTCAAAGTT (shSesn3).  
535 VSV-g pseudotyped lentiviral particles were produced, concentrated and titrated in HEK293  
536 cells as described<sup>9</sup>.

537 Cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated FCS, 100  
538 U/ml penicillin, 100 mg/ml streptomycin, 50 µg/ml gentamicin, 2 mM L-glutamine (all from  
539 Invitrogen) and 0.5 ng/ml anti-mycoplasma (Bio-Rad) at 37 °C in a humidified 5% CO<sub>2</sub>  
540 incubator. Purified human highly differentiated CD28<sup>-</sup>CD8<sup>+</sup> T cells were activated in the  
541 presence of plate-bound anti-CD3 (purified OKT3, 0.5 µg/ml) plus rhIL-2 (R&D Systems, 10  
542 ng/ml), and then transduced with pHIV1-Siren lentiviral particles (multiplicity of infection (MOI)  
543 = 10) 72 h after activation.

### 544 ***Flow cytometry and phospho-flow***

545 Multi-parameter flow cytometry was used for phenotypic and functional analyses of PBMC.  
546 For analysis of surface markers, staining was performed at 4°C for 30 min in the presence of  
547 saturating concentrations of antibodies (listed in Supplementary table 5) and a live/dead

548 fixable Near-Infrared stain (Thermo Scientific, L10119). For intracellular analysis of cytokine  
549 secretion, cytotoxic granule expression, and sestrin 1, sestrin 2, DAP12, and DAP10  
550 expression, cells were fixed and permeabilized with the Fix & Perm® Kit (Invitrogen, Life  
551 Technologies, UK), before incubation with indicated antibodies or the respective isotype  
552 controls. For imaging cytometry, samples were acquired on an Amnis ImageStreamX Mk2  
553 using INSPIRE software, magnification 60X. Data were analysed using IDEAS v6.2 software  
554 (*Amnis*). Co-localization of signals was determined on a single cell basis using bright detail  
555 similarity (BDS) score analysis. Co-localization was considered with  $BDS \geq 2.0$ .

556 For Phospho-Flow cytometry, after staining for surface markers, CD8<sup>+</sup> T cells were stimulated  
557 with anti-CD3 (purified OKT3, 10 µg/mL) for 30 minutes on ice, followed by crosslinking with  
558 goat anti-mouse IgG antibody during 30 minutes on ice. Cells were then transferred to an  
559 incubator at 37°C, and stimulation was terminated after 10 minutes, with immediate fixation  
560 with Cytifix Buffer (PBS containing 4% paraformaldehyde, BD Biosciences) followed by  
561 permeabilization with ice-cold Perm Buffer III (PBS containing 90% methanol, BD  
562 Biosciences) and staining with antibodies for phospho-proteins (listed in **Table 2**) for 30  
563 minutes at room temperature. Samples were acquired on a LSR II flow cytometer (BD  
564 Biosciences) and analysed using FlowJo software (TreeStar).

#### 565 ***Cytotoxic assays - CD107a degranulation assay***

566 Freshly isolated NK and CD8<sup>+</sup> T cell subsets were incubated at 37°C for 6 h with K562 or C1R-  
567 MICA/C1R cells, at a fixed effector to target (E:T) ratio of 2:1, in the presence of APC-  
568 conjugated CD107a antibody (BD Biosciences), as previously described<sup>68</sup>. Brefeldin A  
569 (1µg/ml; Sigma-Aldrich) and Monensin (1 µg/ml; Sigma-Aldrich) were added in the final 5h-  
570 incubation period. Effector cells incubated alone in the presence phorbol-12-myristate-13-  
571 acetate (PMA, 50 ng/ml, Sigma-Aldrich) with ionomycin, (250 ng/ml, Sigma-Aldrich) were used  
572 as positive control whereas medium alone served as unstimulated (US) control. After  
573 incubation, cells were stained for surface markers for 30 min on ice, followed by intracellular

574 detection of cytokines (TNF- $\alpha$  and IFN- $\gamma$ ) and CD107a expression and analysed by flow  
575 cytometry.

### 576 ***Cell lines***

577 K562 (human erythroleukemic) cell line was purchased from the European Collection of Cell  
578 cultures (ECCAC, UK) and cultured in 25 cm<sup>2</sup> flasks (Nunc) in complete RPMI-1640. B-  
579 lymphoblastoid cell lines, C1R and C1R transfected with MICA\*008 (C1RMICA) were kindly  
580 provided by Professor Antoine Toubert (INSERM UMR1160, Paris) and maintained in  
581 complete RPMI-1640 in the presence of the aminoglycoside antibiotic G-418 (Sigma, G8168)  
582 for selection of transfected cells<sup>49</sup>.

### 583 ***Immunoblotting***

584 Human CD8<sup>+</sup> T cell subsets purified using immunomagnetic separation (MACS) according to  
585 CD27/CD28 expression were stimulated with anti-CD3 (purified OKT3, 10  $\mu$ g/mL) or anti-  
586 NKG2D (1D11, 10  $\mu$ g/mL) before lysis. Cells were normalized by equal cell number, harvested  
587 and lysed in ice-cold Radio-Immunoprecipitation Assay (RIPA) buffer (Sigma-Aldrich, UK),  
588 supplemented with protease and phosphatase inhibitors (GE Healthcare, Amersham, UK),  
589 during 30 minutes on ice. Cell lysates were processed for immunoblot analysis as described<sup>6</sup>.

### 590 ***Immunoprecipitation***

591 Human CD8<sup>+</sup> T cells were separated into CD28<sup>+</sup>/CD28<sup>-</sup> fractions (to obtain sufficient number  
592 of cells for analysis) and stimulated with anti-NKG2D (1D11, 10  $\mu$ g/mL) or isotype control, for  
593 30 minutes at 4 °C. Lysates from 1x10<sup>7</sup> cells were prepared with ice-cold HNGT buffer (50  
594 mM HEPES, pH 7.5, 150 mM EDTA, 10 mM sodium pyrophosphate, 100 mM sodium  
595 orthovanadate, 100 mM sodium fluoride, 10 mg/ml aprotinin, 10 mg/ml leupeptin and 1 mM  
596 phenylmethylsulfonyl fluoride), for 30 minutes on ice. Cell lysates were incubated overnight at  
597 4°C with anti-NKG2D antibody (clone 5C6, Santa Cruz) or control antibody, followed by  
598 precipitation with 10  $\mu$ L of pre-washed protein A/G agarose beads (sc-2003, Santa Cruz) for  
599 3 h at 4°C on a rotary shaker. After extensive washing in HGNT buffer, supernatants were



600 recovered and processed for immunoblot analysis, as described above. Co-  
601 Immunoprecipitated proteins were detected after incubation with primary antibodies followed  
602 by incubation with mouse anti-rabbit IgG (conformation-specific antibody; L27A9; Cell  
603 Signaling) or mouse anti-rabbit IgG light chain (L57A3; Cell Signaling) and by a secondary  
604 anti-mouse IgG antibody (7076; Cell Signaling).

#### 605 **Mice**

606 *Sesn1*<sup>-/-</sup> and *Sesn2*<sup>-/-</sup> mice were described previously<sup>7</sup>. The mouse ageing study was  
607 performed at the University of Michigan, where the animal procedures were approved by the  
608 Institutional Animal Care & Use Committee and overseen by the Unit for Laboratory Animal  
609 Medicine. All mice were rested for at least 10 days before being used for *in vivo* studies.  
610 Animals were housed under standard conditions, maintained in a 12 h/12 h light/dark cycle at  
611 22 °C ± 1 °C and given food and tap water *ad libitum* in accordance with United Kingdom  
612 Home Office regulations (PPL-P69E3D849) and the NIH guideline.

#### 613 **Murine delayed type hypersensitivity model**

614 Knockout and age-matched (18-month-old) C57BL66J WT control mice were imported from  
615 the University of Michigan. Young (~6 weeks) WT mice were purchased separately from  
616 *Charles River*. All mice were male. The methylated BSA (mBSA) delayed type hypersensitivity  
617 model was performed as described previously<sup>50</sup>. Mice were sensitized at the base of the tail  
618 with a 50 µl injection of mBSA in Freund's complete adjuvant (20 mg/ml solution of mBSA in  
619 saline emulsified with an equal volume of Freund's adjuvant containing 4 mg/ml  
620 *Mycobacterium tuberculosis* H37Ra, *Sigma Aldrich*). An immune response was evoked 14  
621 days later by subplantar challenge with 50 µl of mBSA in saline (1 mg/ml). The contralateral  
622 paw received a saline-only injection and served as a control. The immune response is reported  
623 as the difference in paw swelling between left and right paws as determined using callipers  
624 (POCO2, Kroeplin). Mice were sacrificed 7 days post-challenge, according to Schedule 1,  
625 using an increasing concentration of CO<sub>2</sub>. Death was confirmed by cervical dislocation.

626 Spleens and inguinal lymph nodes were obtained, weighed and dispersed through a 70  $\mu\text{m}$   
627 followed by a 35  $\mu\text{m}$  sterile cell sieve (*Becton Dickinson*) to yield single cell suspensions. Cell  
628 numbers were enumerated by haemocytometer and up to  $10^6$  cells were used for  
629 polychromatic flow cytometry.

### 630 ***In vivo cytotoxicity***

631 24-month-old knockout (*Sesn1<sup>-/-</sup>Sesn2<sup>-/-</sup>Sesn3<sup>+/-</sup>*) males were imported from the University of  
632 Michigan. Age-matched wild type female C57Bl/6J mice were purchased from Envigo. Natural  
633 killer cells were depleted by intraperitoneal injection of 100  $\mu\text{g}$  anti-NK1.1 antibody (PK136,  
634 BioXCell) 24 hours before cell challenge. The high Rae-1 expressing myeloma cell line 5TGM  
635 was labeled with 5  $\mu\text{M}$  CFSE, while splenocytes stained with 0.5  $\mu\text{M}$  were used as Rae-1<sup>-</sup>  
636 controls. Both cell types were mixed at equal ratios and  $2 \times 10^7$  were co-injected i.v. Mice were  
637 left for 6 hours before being sacrificed. As a measure of Rae-1 directed killing, the ratio of  
638 CFSE<sup>hi</sup> compared to CFSE<sup>lo</sup> was used to determine Rae-1<sup>+</sup> cell retrieval and specific lysis.

### 639 ***Statistical analysis***

640 Statistical analysis was performed using GraphPad Prism version 6.00. Tests were used to  
641 determine data distribution and depending on the normality of the data, comparisons were  
642 performed using the Student *t* test (for two groups, parametric) or the non-parametric Mann–  
643 Whitney U test (for two groups, unpaired) and the Wilcoxon signed rank test (for two groups,  
644 paired) with two-tailed *P* values unless otherwise stated. When comparing more than two  
645 groups, we used one-way ANOVA (parametric, > 2 groups, unpaired), repeated measures  
646 ANOVA (parametric, > 2 groups, paired), Kruskal–Wallis (non-parametric, > 2 groups,  
647 unpaired) or Friedman (non-parametric, > 2 groups, paired) tests with post-correction for  
648 multiple comparisons, as appropriate. The two-way ANOVA test was used to compare the  
649 effects of two independent variables between groups. Linear regression analysis was  
650 performed to generate lines of best fit and correlations between variables were analysed using  
651 Pearson's or Spearman's rank correlation coefficient (*r*). Differences were considered

652 significant when  $p < 0.05$  (\*),  $p < 0.01$  (\*\*),  $p < 0.001$ (\*\*\*) and  $p < 0.0001$  (\*\*\*\*). Data are  
653 presented as means  $\pm$  standard error of the mean (SEM) unless otherwise stated.

#### 654 **Data and materials availability**

655 The data that support the findings of this study are available from the corresponding author  
656 upon request. The complete microarray dataset is available online from the NCBI Gene  
657 Expression Omnibus public repository (GEO accession number GSE98640).

658 The single cell RNA-seq data are available on EGA (Accession number EGAS00001004255).

659

#### 660 **References**

- 661 1. Akbar, A. N., Beverley, P. C. & Salmon, M. Will telomere erosion lead to a loss of T-cell  
662 memory? *Nature Reviews Immunology* **4**, nri1440 (2004).
- 663 2. Gray, D. A role for antigen in the maintenance of immunological memory. *Nat Rev*  
664 *Immunol* **2**, nri706 (2002).
- 665 3. Mitri, D. *et al.* Reversible Senescence in Human CD4+CD45RA+CD27- Memory T  
666 Cells. *The Journal of Immunology* **187**, 2093–2100 (2011).
- 667 4. Henson, S. M. *et al.* p38 signaling inhibits mTORC1-independent autophagy in senescent  
668 human CD8+ T cells. *Journal of Clinical Investigation* **124**, 4004–4016 (2014).
- 669 5. Lanna, A., Henson, S. M., Escors, D. & Akbar, A. N. The kinase p38 activated by the  
670 metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T  
671 cells. *Nature immunology* **15**, 965–72 (2014).
- 672 6. Tarazona, R. *et al.* Increased expression of NK cell markers on T lymphocytes in aging  
673 and chronic activation of the immune system reflects the accumulation of effector/senescent  
674 T cells. *Mechanisms of Ageing and Development* **121**, 77–88 (2001).
- 675 7. Lanna, A. *et al.* A sestrin-dependent Erk-Jnk-p38 MAPK activation complex inhibits  
676 immunity during aging. *Nature immunology* **18**, 354–363 (2017).
- 677 8. Dunne, P. J. *et al.* Quiescence and functional reprogramming of Epstein-Barr virus (EBV)–

678 specific CD8+ T cells during persistent infection. *Blood* **106**, 558–565 (2005).

679 9. Pereira, B. I. *et al.* Senescent cells evade immune clearance via HLA-E-mediated NK and  
680 CD8+ T cell inhibition. *Nat Commun* **10**, 2387 (2019).

681 10. Krizhanovsky, V., Yon, M., Dickins, R., Hearn, S., Simon, J., Miething, C., Yee, H.,  
682 Zender, L., Lowe, S. (2008). Senescence of Activated Stellate Cells Limits Liver Fibrosis *Cell*  
683 134(4), 657-67.

684 11. Dominguez, C. X. *et al.* The transcription factors ZEB2 and T-bet cooperate to program  
685 cytotoxic T cell terminal differentiation in response to LCMV viral infection. *J Exp*  
686 *Medicine* **212**, 2041–2056 (2015).

687 12. Kovalovsky, D. *et al.* PLZF Induces the Spontaneous Acquisition of Memory/Effector  
688 Functions in T Cells Independently of NKT Cell-Related Signals. *J Immunol* **184**, 6746–6755  
689 (2010).

690 13. Raberger, J., Schebesta, A., Sakaguchi, S., Boucheron, N., Blomberg, K., Berglöff, A.,  
691 Kolbe, T., Smith, C., Rüllicke, T., Ellmeier, W. (2008). The transcriptional regulator PLZF  
692 induces the development of CD44 high memory phenotype T cells Proceedings of the  
693 National Academy of Sciences **105**(46), 17919-17924.

694 14. Liu, D. *et al.* Integrin-Dependent Organization and Bidirectional Vesicular Traffic at  
695 Cytotoxic Immune Synapses. *Immunity* **31**, 99–109 (2009).

696 15. Bernardini, G., Sciumè, G. & Santoni, A. Differential chemotactic receptor requirements  
697 for NK cell subset trafficking into bone marrow. *Front Immunol* **4**, 12 (2013).

698 16. van Lier, R. A., ten Berge, I. J. & Gamadia, L. E. Human CD8(+) T-cell differentiation in  
699 response to viruses. *Nature reviews. Immunology* **3**, 931–9 (2003).

700 17. Rufer, N. *et al.* Ex vivo characterization of human CD8+ T subsets with distinct  
701 replicative history and partial effector functions. *Blood* **102**, 1779–1787 (2003).

702 18. Henson, S. M. *et al.* KLRG1 signaling induces defective Akt (ser473) phosphorylation  
703 and proliferative dysfunction of highly differentiated CD8+ T cells. *Blood* **113**, 6619–6628

704 (2009).

705 19. Plunkett, F. J. *et al.* The Loss of Telomerase Activity in Highly Differentiated  
706 CD8+CD28–CD27– T Cells Is Associated with Decreased Akt (Ser473)  
707 Phosphorylation. *The Journal of Immunology* **178**, 7710–7719 (2007).

708 20. Henson, S. M., Riddell, N. E. & Akbar, A. N. Properties of end-stage human T cells  
709 defined by CD45RA re-expression. *Current Opinion in Immunology* **24**, 476–481 (2012).

710 21. Aktas, E., Kucuksezer, U., Bilgic, S., Erten, G. & Deniz, G. Relationship between  
711 CD107a expression and cytotoxic activity. *Cell Immunol* **254**, 149–154 (2009).

712 22. Lanier, L. L. NKG2D Receptor and Its Ligands in Host Defense. *Cancer Immunol*  
713 *Res* **3**, 575–582 (2015).

714 23. Wu, J. *et al.* An Activating Immunoreceptor Complex Formed by NKG2D and  
715 DAP10. *Science* **285**, 730–732 (1999).

716 24. Upshaw, J. L. *et al.* NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1  
717 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. *Nat*  
718 *Immunol* **7**, 524–532 (2006).

719 25. Diefenbach, A. *et al.* Selective associations with signaling proteins determine stimulatory  
720 versus costimulatory activity of NKG2D. *Nat Immunol* **3**, ni858 (2002).

721 26. Gilfillan, S., Ho, E. L., Cella, M., Yokoyama, W. M. & Colonna, M. NKG2D recruits two  
722 distinct adapters to trigger NK cell activation and costimulation. *Nat Immunol* **3**, ni857  
723 (2002).

724 27. Wu, J., Cherwinski, H., Spies, T., Phillips, J. H. & Lanier, L. L. Dap10 and Dap12 Form  
725 Distinct, but Functionally Cooperative, Receptor Complexes in Natural Killer Cells. *J Exp*  
726 *Medicine* **192**, 1059–1068 (2000).

727 28. Akondy, R. S. *et al.* Origin and differentiation of human memory CD8 T cells after  
728 vaccination. *Nature* **552**, 362 (2017).

729 29. Akondy, R. S. *et al.* The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional  
730 Human Memory CD8+ T Cell Response. *The Journal of Immunology* **183**, 7919–7930

731 (2009).

732 30. Wang, X. *et al.* Human invariant natural killer T cells acquire transient innate  
733 responsiveness via histone H4 acetylation induced by weak TCR stimulation. *J Exp*  
734 *Medicine* **209**, 987–1000 (2012).

735 31. Mingueneau, M. *et al.* Loss of the LAT Adaptor Converts Antigen-Responsive T Cells  
736 into Pathogenic Effectors that Function Independently of the T Cell  
737 Receptor. *Immunity* **31**, 197–208 (2009).

738 32. Wencker, M. *et al.* Innate-like T cells straddle innate and adaptive immunity by altering  
739 antigen-receptor responsiveness. *Nature Immunology* **15**, ni.2773 (2013).

740 33. Pawelec, G. Immunosenesescence: Role of cytomegalovirus. *Exp Gerontol* **54**, 1–5  
741 (2014).

742 34. Khan, N. *et al.* Herpesvirus-Specific CD8 T Cell Immunity in Old Age: Cytomegalovirus  
743 Impairs the Response to a Coresident EBV Infection. *The Journal of*  
744 *Immunology* **173**, 7481–7489 (2004).

745 35. Jackson, S. E. *et al.* CMV immune evasion and manipulation of the immune system with  
746 aging. *GeroScience* **39**, 273–291 (2017).

747 36. Vallejo, A. N. *et al.* Expansions of NK-like  $\alpha\beta$ T cells with chronologic aging: Novel  
748 lymphocyte effectors that compensate for functional deficits of conventional NK cells and T  
749 cells. *Ageing Research Reviews* **10**, 354–361 (2011).

750 37. Coppé, J.-P. P. *et al.* Senescence-associated secretory phenotypes reveal cell-  
751 nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. *PLoS biology* **6**,  
752 2853-68 (2008).

753 38. Campisi, J. & di Fagagna, F. Cellular senescence: when bad things happen to good  
754 cells. *Nature Reviews Molecular Cell Biology* **8**, 729–740 (2007).

755 39. Baker, D. J. *et al.* Naturally occurring p16Ink4a-positive cells shorten healthy  
756 lifespan. *Nature* **530**, 184–189 (2016).

757 40. Baker, D. J. *et al.* Clearance of p16Ink4a-positive senescent cells delays ageing-  
758 associated disorders. *Nature* **479**, 232–6 (2011).

759 41. Sagiv, A. *et al.* NKG2D ligands mediate immunosurveillance of senescent  
760 cells. *Aging* **8**, 328–44 (2016).

761

762 **Methods references**

763 42. Callender, L. A. *et al.* Human CD8+ EMRA T cells display a senescence-associated  
764 secretory phenotype regulated by p38 MAPK. *Aging Cell* **17**, (2018).

765 43. Gérard, S., Sibénil, S., Martin, E., Lenoir, C., Aguilar, C., Picard, C., Lantz, O., Fischer, A.,  
766 Latour, S. (2013). Human iNKT and MAIT cells exhibit a PLZF-dependent proapoptotic  
767 propensity that is counterbalanced by XIAP *Blood* **121**(4), 614-623.

768 44. Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell  
769 doublets in single-cell transcriptomic data. *bioRxiv*(2018). doi:10.1101/357368

770 45. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression  
771 data analysis. *Genome Biol.* **19**, 15 (2018).

772 46. Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of  
773 single-cell gene expression data. *Nat. Biotechnol.* **33**, 495–502 (2015).

774 47. McInnes, L., Healy, J. & Melville, J. UMAP: Uniform Manifold Approximation and  
775 Projection for Dimension Reduction. *arXiv:1802.03426[cs, stat]* (2018).

776 48. Park, J.-E., Polanski, K., Meyer, K. & Teichmann, S. A. Fast Batch Alignment of  
777 SingleCell Transcriptomes Unifies Multiple Mouse Cell Atlases into an Integrated  
778 Landscape. *bioRxiv*(2018). doi:10.1101/397042

779 49. Allez, M. *et al.* CD4+NKG2D+ T Cells in Crohn's Disease Mediate Inflammatory and  
780 Cytotoxic Responses Through MICA Interactions. *Gastroenterology* **132**, 2346–2358  
781 (2007).

782 50. Trivedi, S. G. *et al.* Essential role for hematopoietic prostaglandin D2 synthase in  
783 the control of delayed type hypersensitivity. *P Natl Acad Sci Usa* **103**, 5179–5184  
784 (2006).

785

## 786 **Figure legends**

### 787 **Fig. 1: Transcriptional signature of human CD8<sup>+</sup> T cell subsets**

788 **a)** Representative image of CD8<sup>+</sup> T cells gated on CD27<sup>+</sup>CD45RA<sup>+</sup> T<sub>N</sub> cell, CD27<sup>+</sup>CD45RA<sup>-</sup>  
789 T<sub>CM</sub> cells, CD27<sup>-</sup>CD45RA<sup>-</sup>T<sub>EM</sub> cells, and CD27<sup>-</sup>CD45RA<sup>+</sup>T<sub>EMRA</sub> cells isolated from the PBMCs  
790 from 6 healthy donors. Numbers in gates represent percentages of cells in each subset from  
791 a representative donor. Similar results were obtained in other experiments. **b)** Heat map of  
792 gene expression of Affymetrix U133 plus 2 microarrays of sorted T<sub>N</sub> and T<sub>EMRA</sub> CD8<sup>+</sup> T cell  
793 subsets, showing downregulated (in yellow) and upregulated genes (in blue). **c)** The relative  
794 fold-change (log<sub>10</sub>) of differentially expressed genes of interest in T<sub>CM</sub>, T<sub>EM</sub> and T<sub>EMRA</sub> CD8<sup>+</sup> T  
795 cell subsets compared to T<sub>N</sub> CD8<sup>+</sup> T cells. The list of genes of interest is shown in  
796 Supplementary table 2 and the complete list of differentially expressed genes from the whole-  
797 transcriptome analysis ( $\geq 2$ -fold change,  $p < 0.05$ , FDR < 0.05%) is available in Supplementary  
798 table 1. **d)** NKR expression T<sub>N</sub>, T<sub>CM</sub>, T<sub>EM</sub>, and T<sub>EMRA</sub> CD8<sup>+</sup> T cells assessed by flow cytometry  
799 on PBMCs from 22 healthy donors (median age = 52, range 25-83). **e)** Representative  
800 immunoblots of proximal TCR components Lck, PLC $\gamma$ 1, LAT and Zap70 on CD27<sup>+</sup>CD28<sup>+</sup>,  
801 CD27<sup>+</sup>CD28<sup>-</sup> and CD27<sup>-</sup>CD28<sup>-</sup> CD8<sup>+</sup> T cells freshly isolated from PBMCs using magnetic  
802 activated cell. Similar data were obtained in 4 independent experiments. Summary data (n =  
803 4) of Lck, Zap70, PLC $\gamma$ 1 and LAT expression normalized to the loading control (GAPDH) and  
804 presented relative to the basal expression in CD27<sup>+</sup>28<sup>+</sup>CD8<sup>+</sup> cells set to 1. **d)** Two-way  
805 ANOVA with Dunnett's post-test correction and **e)** one-way ANOVA with Tukey's correction  
806 ( $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ ,  $****p < 0.0001$ ).

### 807 **Fig. 2: Single cell RNA-seq (scRNA-seq) of T<sub>N</sub> and T<sub>EMRA</sub> CD8<sup>+</sup> T cells**

808 **a)** UMAP visualisation with clusters demarcated by colours identifying 13 CD8<sup>+</sup> T cell clusters  
809 (C0 to C12) from RNA-seq analysis of single-cell sorted IL-7R<sup>+</sup>CD8<sup>+</sup> (n = 37,192 single cells)  
810 and IL-7R<sup>-</sup>CD8<sup>+</sup> (n = 25,151 single cells) T cells from six healthy older donors. **b)** UMAP plot  
811 from **a)** pseudo-coloured to show clustering of IL7-R<sup>+</sup> (in green) and IL7-R<sup>-</sup> (in purple) CD8<sup>+</sup> T  
812 cells as identified during sorting. **c)** UMAP plot from **a)** representing expression values of



813 selected individual genes. Scales show low expression (yellow) to high expression (red). Other  
814 aliases or CD numbers of proteins encoded by the listed genes are shown in brackets.

815 **Fig. 3: NK and senescence markers within T<sub>N</sub> and T<sub>EMRA</sub>**

816 **a)** UMAP plot of single-cell sorted IL-7R<sup>+</sup>CD8<sup>+</sup> and IL-7R<sup>-</sup>CD8<sup>+</sup> T cells from six healthy older  
817 donors. Highlighted clusters were considered as T<sub>N</sub> (C0, C4 and C8) and T<sub>EMRA</sub> (C1, C2 and  
818 C6) compartments. **b)** UMAP plot showing re-clustering of selected T<sub>N</sub> (C0, C4, and C8) and  
819 T<sub>EMRA</sub> (C1, C2, and C6) CD8<sup>+</sup> cells from **a)** (n = 39,634 cells). **c)** UMAP plots representing the  
820 expression values of NK-related genes in re-clustered T<sub>N</sub> and T<sub>EMRA</sub> CD8<sup>+</sup> cells from **b)**. Scales  
821 show low expression (yellow) to high expression (red). **d)** Violin plots of NK-related gene  
822 expression determined by scRNA-seq in T<sub>N</sub> and T<sub>EMRA</sub> CD8<sup>+</sup> T cells clustered as in **b)** (means,  
823 range, and distribution of individual data; n = 39,364 single cells). **e)** UMAP plots showing  
824 expression of senescence-associated determined by scRNA-seq in T<sub>N</sub> and T<sub>EMRA</sub> CD8<sup>+</sup> T cells  
825 re-clustered as in **b)**. Scales show low expression (yellow) to high expression (red). Other  
826 aliases or CD numbers of some gene products are shown in brackets. **f)** Violin plots of  
827 senescence scores calculated based on the average normalized expression of each  
828 senescence-associated gene across T<sub>N</sub> and T<sub>EMRA</sub> CD8<sup>+</sup> cells clustered as in **b)** (means,  
829 range, and distribution of individual data; n = 39,364 single cells). The gene lists used to define  
830 NK- and senescence-scores are given in Supplementary table 4).

831 **Fig. 4: NKG2D-DAP12 complex mediates NK cytotoxicity in CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells**

832 **a)** Box-and-whisker plot of cell-surface CD107a expression of CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup>,  
833 CD27<sup>+</sup>CD28<sup>-</sup>CD8<sup>+</sup>, CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup>, and CD3<sup>-</sup>CD56<sup>+</sup> NK cells isolated from healthy donors  
834 co-cultured with K562 cells at E:T 2:1 (median and range, n = 5). **b)** CD107a expression on  
835 CD28<sup>-</sup>CD8<sup>+</sup> T cells transfected with NKG2D siRNA (siNKG2D) or control siRNA (siCtrl) and  
836 cultured with C1R-MICA or C1R (E:T ratio 2:1) for 6 hours (mean and s.e.m., n = 4). **c)**  
837 Immunoblots (representative of five independent experiments with similar results) and **d)** flow  
838 cytometry (means and s.e.m., n = 12) showing DAP12 expression on CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup>,  
839 CD27<sup>+</sup>CD28<sup>-</sup>CD8<sup>+</sup>, CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup>, and CD3<sup>-</sup>CD56<sup>+</sup> NK cells. **g)** Expression of DAP12 in  
840 lysed CD28<sup>+</sup>CD8<sup>+</sup> T cells and CD28<sup>-</sup>CD8<sup>+</sup> T cells co-immunoprecipitated with antibody against  
841 NKG2D. Loading control, light-chain IgG (IgGL). Whole-cell lysate immunoblot shown as a  
842 control. Representative of two independent experiments. **f)** Phosphorylation of Zap70(Tyr319)  
843 and Syk(Tyr352) in freshly isolated CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells after treated with CD3 mAb  
844 (OKT3, 10 µg/mL, 15 minutes) and/or NKG2D Ab (1D11, 5 µg/mL, 15 minutes). Numbers  
845 indicate relative expression normalized to total Zap70. Representative of 2 experiments. **g)**  
846 Granzyme B expression (left) and IFN-γ secretion (right) in CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup>, CD27<sup>+</sup>CD28<sup>-</sup>

847 CD8<sup>+</sup>, and CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells after stimulation with NKG2D Ab (5 µg/mL, means and  
848 s.e.m., n = 15 donors). **h)** CD107a expression in human CD28<sup>-</sup>CD8<sup>+</sup> T cells transfected with  
849 DAP12 siRNA (siDAP12) or control siRNA (siCtrl) cultured with C1R-MICA\*008 or C1R cells  
850 for 6 hours (E:T ratio 2:1; means and s.e.m., n = 4). Statistical significance determined with  
851 Kruskal-Wallis test in **a)** Friedman test with Dunn's correction in **d)**, two-way ANOVA with  
852 Bonferroni correction in **b)**, **j)** and one-way ANOVA with Tukey's in **g)** (\**p* <0.05, \*\**p* <0.01, \*\*\**p*  
853 <0.001).

854 **Fig. 5: Sestrins and Jnk MAPK dampen TCR signalling in CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells**

855 **a)** Representative histograms of P-CD3ζ in CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup>, CD27<sup>+</sup>CD28<sup>-</sup>CD8<sup>+</sup>, and CD27<sup>-</sup>  
856 CD28<sup>-</sup>CD8<sup>+</sup> T cells stimulated with anti-CD3 (OKT3, 10 µg/mL, 15 minutes). Unstimulated  
857 CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup> are shown as a control. Numbers on histograms represent the mean  
858 fluorescence intensity (MFI) for each subset. Summary data are given (means and s.d., n = 8  
859 donors). **b)** Representative histograms of P-Zap70-Syk in CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup>, CD27<sup>+</sup>CD28<sup>-</sup>  
860 CD8<sup>+</sup>, and CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells stimulated as in **a)**. Unstimulated CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup> are  
861 shown as a control. Numbers on histograms represent the mean fluorescence intensity (MFI)  
862 for each subset. Summary data are given (means and s.d., n = 8). Summary results presented  
863 as the MFI relative to that of DP CD8<sup>+</sup> T cells, set to 1. **c)**, **d)** Expression of Sesn1 **c)** and Sesn2  
864 **d)** proteins determined by flow cytometry in CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup>, CD27<sup>+</sup>CD28<sup>-</sup>CD8<sup>+</sup>, and CD27<sup>-</sup>  
865 CD28<sup>-</sup>CD8<sup>+</sup> T cells (means and s.d., n = 10 donors). **e)** Immunoblot of Sesn2 and p-Jnk  
866 (T183/Y185) in CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup>, CD27<sup>+</sup>CD28<sup>-</sup>CD8<sup>+</sup>, and CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells, freshly  
867 isolated from peripheral blood of healthy donors. Representative of three independent  
868 experiments with similar results. Densitometry data from western blots for all donors is also  
869 shown (means and s.e.m., n = 3 donors for p-Jnk, n = 4 donors for Sesn2). Statistical  
870 significance determined with ANOVA with Friedman test and Dunn's post-test correction in **a-**  
871 **b)**, repeated measures one-way ANOVA with Tukey's multiple comparisons test in **c-e)** (\**p*  
872 <0.05, \*\**p* <0.01, \*\*\**p* <0.001, \*\*\*\**p* <0.0001).


873 **Fig. 6: Sestrins regulate DAP12 and NKG2D expression in CD8<sup>+</sup> T cells.**




874 **a)** Expression of DAP12, sestrin 2 and p-Jnk (T183/Y185) in lysed CD28<sup>+</sup>CD8<sup>+</sup> T cells and  
875 CD28<sup>-</sup>CD8<sup>+</sup> T cells immunoprecipitated with NKG2D. Loading control: IgG light chain (IgGL).  
876 Results are representative of two independent experiments. **b)** Cellular localization of Sesn2  
877 (AF488, green), DAP12 (PE, red) and P-Jnk (T183/Y185, AF647, yellow) in CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup>  
878 and CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells. "Sesn2", "DAP12", and "p-Jnk" denote single stain controls in  
879 CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup>. Nuclei are stained with DAPI (blue). Scale bars – 7 µm. **c)** Overlap of Sesn2  
880 and DAP12 or P-Jnk in CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup> and CD27<sup>-</sup>CD28<sup>-</sup>CD8<sup>+</sup> T cells. Bright detail






881 similarity scores exceeding 2 were considered to be overlapping. Data are normalized to the  
882 CD27<sup>+</sup>CD28<sup>+</sup>CD8<sup>+</sup> T cell subset for each donor (means and s.d., n = 6). **d-e**) Isolated human  
883 CD8<sup>+</sup>CD28<sup>-</sup> T cells were transduced with control (shCtrl) or anti-sestrin (shSesn) vectors. **d**)  
884 Representative immunoblot for Sesn2 and DAP12 (representative of two experiments). **e**)  
885 Representative contour plots and summary data of NKG2D expression. Results are presented  
886 relative to cells transduced with shCtrl for each donor, set as 1 (means and s.d., n = 3 donors).  
887 **f**) Frequency of NKG2D and CD28 in isolated CD28<sup>-</sup>CD8<sup>+</sup> T treated with siJnk (means and  
888 s.d., n = 6 donors). **g**) Lck phosphorylation in CD28<sup>-</sup>CD8<sup>+</sup> T cells pre-treated with Jnk inhibitor  
889 (SP-600125, 10 μM) prior to anti-CD3 stimulation (OKT3, 10 μg/ml, 15 minutes; means and  
890 s.d., n = 8 donors). Two-tailed paired Student's *t* tests in **c,f-g**) (\**p* <0.05, \*\**p* <0.01, \*\*\**p*  
891 <0.001).

892 **Fig. 7: Sestrins induce an age-dependent NK phenotype in CD8<sup>+</sup> T cells *in vivo***

893 **a**) Measurement of paw size (normalized to the contralateral, PBS control paw) over time (0h,  
894 4h, 24h, 36h, 2, 3, 4, 5, 6, 7 days) in young wild-type (young WT; n = 4), old WT (n = 10), old  
895 *Sesn1*<sup>-/-</sup> (n = 5) and old *Sesn2*<sup>-/-</sup> (n = 4) mice following intra-plantar treatment with mBSA. **b**)  
896 Area under the curve integration of the time course data shown in **a**) (means and s.d.) **c**)  
897 Representative pseudo-colour density plots showing CD44 vs NKG2D expression on  
898 TCRβ<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup> T cells isolated from spleens of young WT, old WT, old *Sesn1*<sup>-/-</sup>, and old  
899 *Sesn2*<sup>-/-</sup> mice. Frequencies of parent gates are shown in the top right-hand corner. **d**)  
900 Cumulative data of NKG2D expression in splenic TCRβ<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup> T cells from young WT,  
901 old WT, old *Sesn1*<sup>-/-</sup>, and old *Sesn2*<sup>-/-</sup> mice (n = 3 mice per group). **e**) Representative histogram  
902 of DAP12 expression from splenic TCRβ<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup> T cells from young WT, old WT, old  
903 *Sesn1*<sup>-/-</sup>, and old *Sesn2*<sup>-/-</sup> mice. FMO control is shown. Cumulative data shown (n = 3 per  
904 group, n = 1 young WT). **f**) NKG2D expression in splenic NK- and iNKT cells from the same  
905 mice as in **c-d**) (means and s.d., n = 3 mice per group). **g**) Retrieval of Rae-1<sup>+</sup> 5TGM1 cells  
906 as a fraction of injected cells (left panel) and killing and specific lysis of injected Rae-1<sup>+</sup> 5TGM1  
907 cells (right panel) from the spleens of NK-depleted (24h, anti-NK1.1, i.p.) old WT and old  
908 *Sesn1*<sup>-/-</sup>*Sesn2*<sup>-/-</sup>*Sesn3*<sup>+/-</sup> mice 6 hours after i.v. challenge (means and s.d., n = 3 mice per  
909 group). Statistical significance determined with one-way ANOVA with Tukey's multiple  
910 comparisons test in **b,d-g**); two-tailed unpaired Student's *t* tests in **h-i**). (\**p* <0.05, \*\**p* <0.01,  
911 \*\*\**p* <0.001, \*\*\*\**p* <0.0001).





**a****b****c****d****e****f**